JP MORGAN/PUT/VERTEX PHARMACEUTICALS/275/0.1/17.01.25 | Delayed Börse Stuttgart 02:44:51 2024-07-09 am EDT | ||
| 0.1 EUR | -16.67% |
|
| Current month | -33.33% | ||
| 3 months | -81.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-09 | 0.1 | -16.67% |
| 24-07-08 | 0.12 | -7.69% |
| 24-07-05 | 0.13 | -7.14% |
| 24-07-04 | 0.14 | 0.00% |
| 24-07-03 | 0.14 | 0.00% |
Delayed Quote Börse Stuttgart
Last update July 09, 2024 at 02:44 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL09Q4 |
| ISIN | DE000JL09Q41 |
| Date issued | 2023-04-12 |
| Strike | 275 $ |
| Maturity | 2025-01-17 (190 Days) |
| Parity | 10 : 1 |
| Emission price | 2.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.09 € |
|---|---|
| Lowest since issue | 0.1 € |
| Spread | 0.148 € |
| Spread % | 61.67% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
491.6
USD
Average target price
473.1
USD
Spread / Average Target
-3.77%
- Stock Market
- Warrants
- Warrant
